Plasminogen activators in oesophageal carcinoma

British Journal of Surgery

Volumn 83, Issue 8, 1996, Pages 1152-1155

  Hewin, D F ^a   Savage, P B ^a   Alderson, D ^a   Vipond, M N ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR; RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

EID: 0029742666     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830838     Document Type: Article

References (36)

1. Liotta LA. Tumor invasion and metastases: role of the basement membrane. Am J Pathol 1984; 117: 339-48.
2. Blasi F. Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol Suppl 1993; 3: 21-3.
3. Dufy MJ. Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1990; 1: 681-7.
4. DeClerck YA, Ferez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-8.
5. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992; 282: 273-8.
6. Sloane BF, Honn KV. Cysteine proteinases and metastasis. Cancer Metastasis Rev 1984; 3: 249-63.
7. Stephens RW, Golder JP. Novel properties of human monocyte plasminogen activator. Eur J Biochem 1984; 139: 253-8.
8. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 1992; 89: 10686-90.
9. Lala PK, Graham CH. Mechanisms of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metastasis Rev 1990; 9: 369-79.
10. de Jong E, Porte RJ, Knot EAR, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30: 188-94.
11. 2-terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-6.
12. Blasi F. Urokinase and urokinase receptor: a paracrine/ autocrine system regulating cell migration and invasiveness. Biodessays 1993; 15: 105-11.
13. Gelister JSK, Mahmoud M, Lewin MR, Gaffney PJ, Boulos PB. Plasminogen activators in human colorectal neoplasia. BMJ 1986; 293: 728-31.
14. Takai S, Yamamura M, Tanaka K et al. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 1991; 48: 20-7.
15. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992; 50: 345-8.
16. Pujade-Lauraine E, Lu H, Mirshahi S et al. The plasminogenactivation system in ovarian tumors. Int J Cancer 1993; 55: 27-31.
17. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992; 50: 871-3.
18. Gris J-C, Schved J-F, Marty-Double C, Mauboussin J-M, Balmes P. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 1993; 104: 8-13.
19. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994; 73: 1398-405.
20. Sier CFM, Verspaget HW, Griffionen G, Ganesh S, Vloedgraven HJ, Lamers CB. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993; 34: 80-5.
21. Foucre D, Bouchet C, Hacene K et al. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 1991; 64: 926-32.
22. Sier CFM, Verspaget HW, Griffionen G et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991; 101: 1522-8.
23. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 1993; 88: 1928-33.
24. Jankun J, Merrick HW, Goldblatt PJ. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 1993; 53: 135-44.
25. Pedersen H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
26. Bianchi E, Cohen RL. Thor AT et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-6.
27. de Vries TJ, Quax PHA, Denijn M et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
28. Ganesh S, Sier CFM, Heerding MM, Griffionen G. Lamers CBHW, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-2 (Letter).
29. Hermanek P, Sobin LH, eds. TNM Classification of Malignant Tumours. 4th ed. 2nd rev. Berlin: Springer, 1992.
30. Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990; 9: 353-67.
31. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
32. Pyke C, Kristensen P, Ralfkiaer E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-67.
33. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-71.
34. Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost 1990; 16: 230-5.
35. Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen-activator inhibitor type 1 and type 2. Eur J Biochcm 1988; 175: 33-9.
36. Reilly DM, Andreasen PA, Duch M, Nolan N, Lecander I, Duffy MJ. Plasminogen activator inhibitor type 1 and 2 in human breast cancer. Biochem Soc Trans 1992; 20: 88S.